Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Status Recruiting

Clinical Trial Summary

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Clinical Trial Description

Primary: To evaluate the long-term safety and tolerability of seladelpar Secondary: - To evaluate the long-term efficacy of seladelpar - To evaluate the effect of seladelpar on patient-reported outcomes (pruritus) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03301506
Study type	Interventional
Source	CymaBay Therapeutics, Inc.
Contact	Barry Crittenden, MD
Phone	510-293-8800
Email	medinfo@cymabay.com
Status	Recruiting
Phase	Phase 3
Start date	December 12, 2017
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04526665` - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)	Phase 3
Recruiting	`NCT02931513` - sCD163 in PBC Patients - Assessment of Treatment Response
Active, not recruiting	`NCT02924701` - sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Completed	`NCT02659696` - Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
Completed	`NCT02078882` - Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis	Phase 4
Completed	`NCT01603199` - High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis	N/A
Completed	`NCT01389973` - A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid	Phase 2
Completed	`NCT01857284` - Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis	Phase 3
Completed	`NCT05374200` - Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC)	N/A
Recruiting	`NCT02937012` - Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders	Phase 3
Completed	`NCT02376335` - B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis	Phase 2
Recruiting	`NCT01662973` - Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis	Phase 1/Phase 2
Active, not recruiting	`NCT04751188` - A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis	Phase 3
Recruiting	`NCT04514965` - Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Recruiting	`NCT03668145` - Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis	N/A
Completed	`NCT02955602` - Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)	Phase 2
Completed	`NCT02557360` - Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis	Phase 4
Recruiting	`NCT01440309` - Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis	Phase 1
Completed	`NCT01249092` - Pentoxifylline for Primary Biliary Cirrhosis	Phase 2
Completed	`NCT01510860` - Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis	Phase 4